StockMarketWire.com - Biotherapeutics company PureTech Health welcomed news that founded entity Akili had received a CE mark for its digital-based treatment for attention deficit hyperactivity disorder.
The EndeavorRx treatment was not yet available in Europe, though the CE mark enabled Akili to market it in European Economic Area member countries.
The CE mark followed last week's US Food and Drug Administration decision, which made EndeavorRx the first FDA-cleared prescription treatment delivered through a video game.
The FDA decision also represented the first game-based therapeutic to be granted marketing authorisation by the FDA for any type of condition.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.